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Abstract
Background: Direct empirical evidence for the existence of outcome reporting bias is
accumulating and this source of bias is recognised as a potential threat to the validity of meta-
analysis of randomised clinical trials.
Methods: A method for calculating the maximum bias in a meta-analysis due to publication bias is
adapted for the setting where within-study selective non-reporting of outcomes is suspected, and
compared to the alternative approach of missing data imputation. The properties of both methods
are investigated in realistic small sample situations.
Results: The results suggest that the adapted Copas and Jackson approach is the preferred method
for reviewers to apply as an initial assessment of robustness to within-study selective non-
reporting.
Conclusion: The Copas and Jackson approach is a useful method for systematic reviewers to
apply to assess robustness to outcome reporting bias.
Background
Publication bias, whereby an entire study is either pub-
lished or not depending on its results, is recognised as a
potential threat to the validity of any meta-analysis.
Empirical research suggests that published work is more
than twice as likely to be statistically significant (p < 0.05)
than unpublished research [1]. Several different methods
for the identification of and adjustment for this source of
bias are available [2]. More recently, asymptotic results
have been presented that allow the meta-analyst to esti-
mate the maximum bias possible in the treatment effect
estimate assuming a certain number of trials have not
been published [3]. Although the method is proposed as
a sensitivity analysis, by varying the number of trials
assumed to be missing, rather than a correction for bias, it
is still important to investigate how well the result holds
since meta-analyses typically include only 5–10 studies.
Copas and Jackson suggest bootstrapping as a method for
doing this however this is unlikely to be implemented by
systematic reviewers unless made available in meta-analy-
sis software.
Within-study selective reporting, or outcome reporting
bias, has been defined as 'the selection of a subset of the
original variables recorded for inclusion in publication of
trials' [4]. This may include the situation where only one
of several outcomes measuring similar things may be
reported, e.g. weight gain at three or six months, or it may
relate to a subtly different selection issue where a particu-
lar outcome is not reported on the basis of the results
obtained [5]. Direct empirical evidence for the existence
of such bias is accumulating [6,7]. In a meta-analysis it is
often the case that a total number of eligible studies k are
identified but only n (k > n) report the data of interest. The
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and try to establish whether the particular outcome has
been collected but not reported. This should ideally
involve contact with the original trialists which may result
in missing data being made available or it may confirm
that the outcome data were not recorded [8]. However it
is likely that in a subset of these studies, m (≤ k-n) say, no
such information is forthcoming. If the level of suspicion
that selective non-reporting has occurred in these m stud-
ies is high, it has been recommended that a sensitivity
analysis be undertaken assuming such bias has occurred
[8].
We have previously proposed and applied a method for
imputing data in this setting when the outcome of interest
is binary and each trial compares two treatments [8].
Applying the Copas and Jackson bound with known m is
easier to compute than the imputation method and there-
fore potentially very useful as an initial sensitivity analysis
to assess robustness to extreme within-study selective
non-reporting. In this paper we present a simulation study
undertaken to assess how the two methods perform when
bias arises as a result of various realistic suppression mod-
els.
Methods
In sections 2.1 and 2.2 we describe the two methods of
bias adjustment based on theoretical considerations and
imputation respectively. Each method is applied to five
meta-analyses from a cohort previously described [8].
Some discrepancies between results from the two meth-
ods were noted. In section 2.3 we describe a simulation
study undertaken to gain an understanding of how the
two methods perform in realistic meta-analysis and trial
suppression model settings.
2.1 Maximum bias bound
For a given number of unpublished studies, m, the maxi-
mum bias, b, in the treatment effect estimate is given by
the formula
where n is the number of studies reporting data and σi is
the standard error of the treatment effect estimate in study
i [3]. The approach assumes that larger studies (with small
standard error) are more likely to be published than
smaller studies (with larger standard error). The number
of unpublished studies is usually unknown and thus sen-
sitivity analysis, varying the unknown number of unpub-
lished studies, m, is recommended. In the context of
within-study selective non-reporting, the number of stud-
ies found to be eligible, where the outcome is known or
suspected to have been measured but no results were pre-
sented, is known. If we take m to equal this number, (2.1)
can be used to assess the robustness to this form of bias. A
pooled effect estimate is first calculated from the n studies
reporting data and either a fixed or random effects model
as appropriate The bias-adjusted estimate is calculated by
adding the value of this bound to the pooled effect esti-
mate. Either +b or -b is added depending on the direction
of effect such that the estimate is moved closer to the null.
2.2 Imputation of missing data
The maximum possible value for the pooled log odds
ratio was also estimated by imputing missing data, specif-
ically the number of events in each treatment group, for
each of the m studies under the extreme assumption that
the reason they are missing is because the two tailed p-
value from the trial was greater than 0.05, and then com-
bining this with observed data [8]. All possible imputa-
tion combinations are enumerated and in turn are pooled
with the available data from the other n studies to produce
a histogram of the meta-analysis estimates. For those
examples where τ2 > 0, random effects estimates were also
calculated incorporating the between-study variance esti-
mated from the observed data. The maximum imputa-
tion-adjusted estimate for the pooled log odds ratio is
taken from the distribution of all possible values under
this imputation method. An assessment is then made as to
whether the inference is robust to the extreme value of the
histogram or not. This approach is attractive since estab-
lishing robustness to the most extreme scenario avoids the
need to undertake more complex analyses.
The imputation can be constrained by using information,
either in the report or from clinical knowledge, to reduce
the range of the possible number of events in a particular
treatment group. For example, reported data from an asso-
ciated outcome such as cancer-specific mortality may be
taken as the lower limit for all-cause mortality. Uncon-
strained data were imputed for all examples. Constrained
data were imputed for two reviews as follows [8]. In the
cancer example, information from trial reports on sub-
groups and infection-related mortality was used to limit
the range of the possible number of overall deaths. In the
immunoglobulin review, by definition the number of
serious infections had to be at least equal to the number
of events reported for either sepsis or death from infec-
tion, providing a lower bound.
2.3 Simulation study
Data for the treatment group were simulated from a
Bin(N, pt) distribution, for the control group from a
Bin(N, pc) distribution. The choice of pt and pc deter-
mines the log odds ratio, log(OR). The sample size, N, was
b
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Trials 2007, 8:9 http://www.trialsjournal.com/content/8/1/9varied across trials according to a normal distribution
with mean Nµ and standard deviation υ * Nµ where υ
could take values between 0 and 1 with increasing values
providing greater sample size variability between trials
within a meta-analysis. A lower limit for N was applied
such that values of N could not be less than 10 by setting
any values generated less than this equal to 10. Data were
simulated from k = n +m trials.
The true relative treatment effect was varied with values of
the odds ratio taken as 1, 0.7, 0.5, and 0.3 by setting pt
equal to 0.25 and varying the value of pc. The total
number of trials before suppression, k = n + m, was taken
as 5,6,7,8,10, and 15 with the value of m allowed to take
values equal to but not greater than n. Trial size was varied
by taking values for Nµ of 25, 50, 75, 100, 150, 200, and
300 and υ of 0.05, 0.15, and 0.35.
Three selection mechanisms have been considered: stand-
ard errors, one- and two-tailed p-values. Suppression on
the basis of one- and two-tailed p-values and standard
errors is not the same as the selection mechanism result-
ing in the Copas and Jackson bias bound being attained.
However our objective in this paper is to assess how
robust the methods are to realistic suppression models. A
selection mechanism based on standard errors alone will
not systematically bias the results of a meta-analysis,
although there will be some loss of precision. Selection
mechanisms based on one and two-tailed p-values will
provide similar results the further the true effect is from
the null. However there will be differences in the studies
suppressed and resulting bias when the true odds ratio is
close to or equal to one. In this situation suppression
based on one-tailed p-values will systematically bias the
results in one direction by suppressing a corner of the fun-
nel plot producing an asymmetrical funnel, while sup-
pression using two tailed p-values will produce a hollow
funnel similar to suppression based on standard errors
and will not systematically bias results in a particular
direction. Therefore of the three selection mechanisms
one-tailed p-value selection will produce the strongest
bias and is arguably the most realistic suppression mech-
anism as it allows for differential selection according to
the direction of the treatment effect.
The true bias in the treatment effect estimate was calcu-
lated as the difference between the pooled log(OR) from
all n + m trials (unsuppressed) and the pooled log(OR)
based on the selected trials. The Copas and Jackson bias
bound was calculated using (2.1) above. For each simu-
lated dataset, the difference between the pooled log(OR)
from all n + m trials (unsuppressed) and the Copas and
Jackson adjusted estimate was calculated. This simulation
exercise was repeated 10,000 times for each combination
of parameters pt, pc, Nµ, and υ. For settings where the
alternative method of imputation may be considered,
namely small study sizes and few trials not reporting the
data of interest, results were also obtained after adjust-
ment via the imputation method for comparison. In set-
tings where larger numbers of larger studies are missing,
imputation was not considered due to the computational
time involved [8].
Results
3.1 Results for real examples
Table 1 shows the pooled estimates for each example fol-
lowing bias adjustment via both imputation and the
Copas and Jackson approach (original data available on
request from the first author). There are some differences
in the results from the two methods. In the cancer meta-
analysis, there is both a small number of studies present-
ing results in the trial publication and a large variability in
the size of the standard errors of the reported effect esti-
mates, and the difference between the results from the two
methods of adjustment is marked. The albumin example
includes a larger number of trials similar in size however,
and the bias-adjusted estimates are almost identical.
The difference between the two estimates is most marked
in the cancer example with the imputation approach
resulting in a much greater bias adjustment. Clearly the
smallest studies are not suppressed here but neither are
they in the other examples where the methods gave more
similar results. Motivated by this example in particular,
our aim in the rest of this paper is to understand how the
two methods perform in a variety of settings via a simula-
tion study.
3.2 Simulation study
Figures 1, 2, 3, 4, 5, 6 show the results of the simulation
study for the effects of increasing the treatment effect size
and variability in trial size around the average shown
when suppression is based on the one-tailed p-value. The
median difference between the true bias and the Copas
and Jackson bias bound is plotted against the median true
bias, where median values have been found from the dis-
tribution of values across the 10,000 simulated datasets.
The plots show that, under the selection model based on
one-tailed p-values, the bias increases as the number of
suppressed trials increases, and the Copas and Jackson
bias bound overestimates the bias, as expected. This con-
servatism increases as the number of suppressed trials
increases. These results were similar across all three sup-
pression models. Importantly these results provide infor-
mation on the degree of overestimation in realistic
settings.
Table 2 shows the 2.5th, 50th and 97.5th centiles of the
distribution of the difference between the pooled log(OR)Page 3 of 12
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Trials 2007, 8:9 http://www.trialsjournal.com/content/8/1/9from all n + m trials (unsuppressed) and the bias-adjusted
estimates from the two methods for selected simulation
parameters. The number of trials has been chosen to be
five or 10 since most meta-analyses fall into this range.
The results indicate that for a meta-analysis that includes
a small number of small trials, the bias could be substan-
tially underestimated in a proportion of cases. This was
not the case however for selection based on standard
errors. For suppression based on one- and two-tailed p-
values, the accuracy of the Copas and Jackson estimate
increased with increasing number of trials, larger trial size,
decreased trial size variability and larger treatment effects.
For suppression based on standard errors, the accuracy of
the Copas and Jackson estimate increased with increasing
number of trials, larger trial size, increased trial size varia-
bility and smaller treatment effects.
The simulation results demonstrate that the imputation
method leads to systematically greater over-adjustment
for bias compared to the Copas and Jackson method. We
believe this to be the explanation for the difference
between the results of the two methods in the cancer
example shown in Table 1.
Discussion
In this paper we advocate that robustness of the meta-
analysis to outcome reporting bias be assessed where
there is a high level of suspicion that within-study selec-
tive reporting has occurred. We recommend sensitivity
analysis rather than adjustment, since correction for bias
is impossible without knowledge of the exact selection
mechanism operating. Understanding selection bias is
made all the more difficult when one recognises that the
process may vary across different fields, for example
mechanisms operating in genetic epidemiology may dif-
fer from clinical trials [9].
In some instances it may be obvious that an outcome was
measured even if not reported given the other outcomes
included in a trial publication. For example, if cause-spe-
cific mortality is reported then overall mortality must
have been measured, even if not reported. In other situa-
tions it may be that a battery of tests or measurements are
usually undertaken together, for example systolic and
diastolic blood pressure, such that if one outcome is
reported but another is not, one should be suspicious that
the latter may have been selectively not reported. How-
ever it is probable that it will often be difficult to assess
whether the outcome was measured and judgment will be
required. The ORBIT (Outcome Reporting Bias In Trials)
project, funded by the UK Medical Research Council, will
attempt to further our understanding of the processes
resulting in selective outcome reporting through inter-
views with clinical trialists. The sensitivity and specificity
of a method for assessing outcome reporting bias in a trial
will be estimated by comparing the assessment based on
all trial reports with the information obtained directly
from trialists.
Researchers often rely on the shape of funnel plots to
detect publication bias however empirical studies suggest
that this may be misleading [10]. Tests for asymmetry in a
funnel plot, including that of Egger, have low power in
typical meta-analyses involving 5–10 trials [11]. It may be
of interest to undertake such a test, and a significant result
may be taken as evidence of asymmetry, however the
sources of bias, be they methodological quality or out-
come reporting bias or some other small study effects,
Table 1: Estimates of bias-adjusted pooled effect in five meta-analysis case studies. FE: fixed effects, RE: random effects.
Example Cancer Immunoglobulin Prostaglandin Albumin Asthma
Original pooled logOR:
FE -0.360 -0.204 -0.071 0.366 -1.258
RE -0.311 -0.142 -1.376
Tau-squared 0 0.111 0.200 0 0.403
N 5 12 18 18 17
(Range of number of participants in trials) (44 to 733) (66 to 2416) (20 to 2517) (10 to 141) (9 to 50)
M 4 3 1 2 1
(Number of participants per trial) (67,91,146, 750) (20,111,235) (60) (16,28) (35)
Copas-adjusted estimate:
FE -0.045 -0.133 -0.033 0.591 -1.153
RE -0.135 -0.050 -1.241
Maximum imputation-adjusted estimate:
FE (constrained) 0.229 -0.111 -0.027 0.589 -1.034
FE (unconstrained) 0.269 -0.110 -0.027 0.589 -1.034
RE -0.154 -0.049 -1.160Page 4 of 12
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Trials 2007, 8:9 http://www.trialsjournal.com/content/8/1/9need further investigation. We prefer not to rely on a non-
significant result as indicative of a lack of bias when evi-
dence from clinical opinion or the trial paper, e.g. p-value
for the outcome reported to be >0.05, clearly raises our
level of suspicion.
Assessing the robustness of a meta-analysis to extreme
within-study selective non-reporting is a useful first stage.
Imputation of missing data has the advantage that it can
be constrained by information given in the report. How-
ever the disadvantages include the programming and
computational time required as well as the limitation to
binary outcomes. The approach suggested in this paper
based on the method of Copas and Jackson has the advan-
tage of being simple to compute. However information
given in the report cannot be used to provide a tighter
bound.
The simulation results provide useful information for
practical meta-analysts. The approach taking the extreme
estimate under imputation has been shown to work
poorly by severe over-adjustment. The Copas and Jackson
adjustment works well for most cases investigated under a
variety of true suppression models. In situations where
the treatment effect is small, trial sizes are small and/or
variable, the number of studies with available data is
small and the number with missing outcome data large,
the approach was found to be less accurate. However, in
these situations the adjustment is conservative, and hence
a meta-analysis which is found to be robust after this
The numbers on each line represent the number of studies suppressedFigure 1
The numbers on each line represent the number of studies suppressed. The y-axis is the difference between the estimated bias 
and the Copas and Jackson bias bound. Simulation results: OR = 1, selection based on one tailed p-values, trial size variability = 
0.05.
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Trials 2007, 8:9 http://www.trialsjournal.com/content/8/1/9degree of adjustment can be considered to be robust to
this form of bias.
There are several issues in this work worthy of further
development and investigation. Firstly, the application of
the method to the problem of within-study selective non-
reporting makes no allowance for the possibility that
there are also further studies that may have collected data
on the outcome of interest that are simply not known
about. As with other papers in this area [8,12], this should
be viewed as an initial exploratory analysis. If the meta-
analysis is not robust to within-study selective reporting
bias this needs to be recognised. If the results are robust,
further work should be undertaken regarding bias due to
unpublished studies. Further work is needed to evaluate
this two-stage approach and also to consider methods to
allow for both within- and between-study selective report-
ing simultaneously. Secondly, the method has only been
investigated for trial settings in the absence of heterogene-
ity of treatment effect across studies. Thirdly, in their work
related to between-study selection bias, Copas and Jack-
son comment that "In reality, significance is not the only
factor taken into account by editors and referees, or even
by authors in deciding whether to write up their study and
submit the article in the first place". It may be however
that statistical significance plays a larger part in the deci-
sion about which outcomes to present within a report.
Further work is needed to understand the selection mech-
The numbers on each line represent the number of studies suppressedFigure 2
The numbers on each line represent the number of studies suppressed. The y-axis is the difference between the estimated bias 
and the Copas and Jackson bias bound. Simulation results: OR = 0.7, selection based on one tailed p-values, trial size variability 
= 0.05.
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The numbers on each line represent the number of studies suppressedFigure 3
The numbers on each line represent the number of studies suppressed. The y-axis is the difference between the estimated bias 
and the Copas and Jackson bias bound. Simulation results: OR = 0.5, selection based on one tailed p-values, trial size variability 
= 0.05.
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The numbers on each line represent the number of studies suppressedFigure 4
The numbers on each line represent the number of studies suppressed. The y-axis is the difference between the estimated bias 
and the Copas and Jackson bias bound. Simulation results: OR = 1, selection based on one tailed p-values, trial size variability = 
0.35.
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The numbers on each line represent the number of studies suppressedFigure 5
The numbers on each line represent the number of studies suppressed. The y-axis is the difference between the estimated bias 
and the Copas and Jackson bias bound. Simulation results: OR = 0.7, selection based on one tailed p-values, trial size variability 
= 0.35.
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The numbers on each line represent the number of studies suppressedFigure 6
The numbers on each line represent the number of studies suppressed. The y-axis is the difference between the estimated bias 
and the Copas and Jackson bias bound. Simulation results: OR = 0.5, selection based on one tailed p-values, trial size variability 
= 0.35.
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Table 2: Selected simulation study results. C&J: Copas and Jackson bias bound approach
Odds ratio Sample size 
variability 
parameter
Mean trial 
size
n m True bias: 
median1
Difference between 
unsuppressed pooled and 
C&J-adjusted: median 
(2.5th, 97.5th) centiles
Difference between 
unsuppressed pooled and 
maximum imputation-
adjusted: median (2.5th, 
97.5th) centiles
1 0.05 25 4 1 0.175 -0.059 (-0.170, 0.117) -0.142 (-0.334, 0.016)
1 0.05 25 3 2 0.345 -0.087 (-0.293, 0.228) -0.323 (-0.653, -0.053)
1 0.05 300 4 1 0.052 -0.014 (-0.048, 0.043)
1 0.05 300 3 2 0.101 -0.021 (-0.084, 0.071)
1 0.35 25 4 1 0.159 -0.055 (-0.161, 0.121) -0.146 (-0.371, 0.030)
1 0.35 25 3 2 0.317 -0.079 (-0.277, 0.220) -0.310 (-0.661, -0.051)
1 0.35 300 4 1 0.053 -0.015 (-0.049, 0.048)
1 0.35 300 3 2 0.103 -0.021 (-0.087, 0.077)
0.5 0.05 25 4 1 0.176 -0.043 (-0.159, 0.153) -0.236 (-0.437, -0.060)
0.5 0.05 25 3 2 0.343 -0.064 (-0.280, 0.277) -0.593 (-0.943, -0.300)
0.5 0.05 300 4 1 0.049 -0.013 (-0.047, 0.045)
0.5 0.05 300 3 2 0.096 -0.019 (-0.082, 0.071)
0.5 0.35 25 4 1 0.155 -0.066 (-0.199, 0.200) -0.358 (-0.650, -0.150)
0.5 0.35 25 3 2 0.314 -0.091 (-0.311, 0.307) -0.546 (-0.946, -0.245)
0.5 0.35 300 4 1 0.044 -0.020 (-0.060, 0.048)
0.5 0.35 300 3 2 0.085 -0.031 (-0.104, 0.075)
1 0.05 25 9 1 0.101 -0.030 (-0.080, 0.039) -0.056 (-0.125, 0.013)
1 0.05 25 5 5 0.479 -0.063 (-0.270, 0.198)
1 0.05 300 9 1 0.031 -0.006 (-0.022, 0.019)
1 0.05 300 5 5 0.138 -0.014 (-0.075, 0.063)
1 0.35 25 9 1 0.101 -0.033 (-0.086, 0.059) -0.077 (-0.182, 0.011)
1 0.35 25 5 5 0.481 -0.068 (-0.274, 0.221)
1 0.35 300 9 1 0.032 -0.007 (-0.025, 0.025)
1 0.35 300 5 5 0.144 -0.015 (-0.080, 0.076)
0.5 0.05 25 9 1 0.105 -0.019 (-0.072, 0.065) -0.126 (-0.206, -0.045)
0.5 0.05 25 5 5 0.477 -0.042 (-0.250, 0.239)
0.5 0.05 300 9 1 0.030 -0.005 (-0.021, 0.019)
0.5 0.05 300 5 5 0.130 -0.013 (-0.072, 0.063)
0.5 0.35 25 9 1 0.102 -0.026 (-0.086, 0.083) -0.027 (-0.096, 0.071)
0.5 0.35 25 5 5 0.467 -0.062 (-0.281, 0.261)
0.5 0.35 300 9 1 0.017 -0.017 (-0.036, 0.020)
0.5 0.35 300 5 5 0.094 -0.043 (-0.110, 0.046)
1 calculated as the median of the distribution of values across simulations for the difference between the pooled log(OR) from all n + m trials and 
the pooled log(OR) based on the selected trials
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anisms operating, and there may be more than one in any
particular setting, in order to better inform statistical
modelling in this area.
Conclusion
The Copas and Jackson approach is a useful method for
reviewers to apply to assess robustness to within-study
selective non-reporting. A question for further research is
whether an improved method can be developed in situa-
tions where the trials are small or there are few trials with
missing outcome data.
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